Skip to main content


Figure 1 | Arthritis Research & Therapy

Figure 1

From: Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study

Figure 1

Absolute serum levels of survivin, rheumatoid factor and antibodies against cyclic citrullinated peptide in the rheumatoid arthritis patients. The levels of survivin were measured in 339 patients from the Better Anti-Rheumatic FarmacOTherapy (BARFOT) cohort of early rheumatoid arthritis at baseline and after 24 months. The patients were divided into four groups based on their survivin status at those two occasions indicated as positive-positive (n = 139), positive–negative (n = 53), negative–positive (n = 18) and negative-negative (n = 129). (A) The absolute levels of survivin are shown at baseline and 24 months. The concentration >0.3 ng/ml indicates high survivin levels (shown as a dashed line). The absolute levels of rheumatoid factor (RF) (IU/ml) (B) and cyclic citrullinated peptide (CCP) (IU/ml) (C) are shown at baseline. Data are shown as IQRs with the medians indicated by lines. (D) The frequency of autoantibodies (RF and antibodies against CCP (aCCP)) within each patient group is shown (%). The Wilcoxon signed-rank test was used for comparison of survivin levels at baseline and 24 months.

Back to article page